Jan 29, 2025, 22:27
CtDNA in CRC Surveillance – Ready for Prime Time?
Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared a post on X:
“ctDNA in CRC is prognostic, but there is no data showing that treatment initiated earlier based upon ctDNA positivity confers improved survival (or QOL). Earlier detection alone does not equal benefit.”
Michael Shusterman, GI Medical Oncologist at Perlmutter Cancer Center at NYU Langone Health, added:
“This 100%. I am not aware of a single predictive study demonstrating survival benefit with ctDNA to date. Also, despite BESPOKE findings, every ctDNA positive patients we have seen has had significant anxiety. We offer it as a prognostic tool, but long term role?”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023